Executive Profiles

Pharma is no stranger to multi-channel marketing, but, according to Novartis's Panos Papakonstantinou, the industry still isn't getting it right.Pharma is no stranger to multi-channel marketing (MCM), but, according to Panos Papakonstantinou, Novartis's Head, Digital Commercial, Europe, the industry still needs to perfect its approach to MCM. Pharm Exec met up with Panos at last week's eyeforpharma Barcelona event to find out what needs to be done. 

Pharm Exec talks value-based healthcare with Professor Bengt Jönsson of the Stockholm School of Economics.

Ambry Genetics' CEO discusses his company's decision to release the genetic information of its customers for free-a rare move, reportedly, for a commercial testing firm.

Anti-corruption NGO Transparency International now has pharma in its sights. Pharm Exec speaks to Sophie Peresson, Director of its Pharmaceuticals & Healthcare Program.

In the patent scrum, a litigator finds her true self.

Pharm Exec talks to Jane Griffiths, Company Group Chairman, Janssen EMEA, about how the relationship between industry and patients is maturing.

Julian Upton sits down with Subhanu Saxena for an update on Cipla's plans to leverage its historic visibility as an emerging market champion to the next level of global leadership in biopharma.

 Ferring Pharmaceuticals’ new manufacturing facility in Parsippany, NJ.  

Pharm Exec talks with David Dosa, a leading physician in geriatric medicine, whose famous work with a cat named oscar in end-of-life diagnostics became the stuff of therapeutic legend.

A Pharm Exec conversation with AmerisourceBergen CEO Steve Collis

Hightlights of Peter Young and Brent Saunders' "fireside chat" about the Allergan CEO’s early entrepreneurial years, his career in the industry, and some of his business philosophies.

Pharm Exec Editor-in-Chief William Looney was on hand to present the CPhI/PharmaBoardroom Award for CEO of the Year at a ceremony in Madrid, Spain, last night.

A recent survey of European biopharma companies and board members revealed that 80 percent of firms find access to qualified senior executives to be a challenge, with the toughest spot to fill being the "seasoned CEO".

The son also rises - how Arjun Handa is making his mark on the family company.

Cracking the code for building a West Coast biotech.

Leading through tough IPR terrain.

In a knowledge industry like biopharma, people are the intangible asset that marks the difference between a status quo or standout performance. Pharm Exec recently convened a panel of industry team leaders and HR specialists at St. Joseph’s University Haub School of Business to parse out some useful best practices in three key areas: talent recruitment and retention; skills training; and workforce diversity.

Rising to the global challenge.

A quick countdown of this year's Top 50 movers and shakers.

The leap from from bench to boardroom.

Juventas's CEO pins his company's success on recruiting top tier talent and maintaining an open culture.

Finding the R&D sweet spot.

Masters of the deal converge in New York to discuss the status of their trade and the forces propelling M&A, licensing, and partnerships in the life sciences for 2015.

Expert panel on rare disease highlights the challenges of serving expectant patients in this uniquely complex market access environment.

Pharm Exec's Emerging Pharma Leaders 2013

Pharm Exec profiles the journey of Healthcare Businesswomen’s Association 2015 Woman of the Year, Denice Torres, whose career demonstrates that doing right starts with finding-and being-yourself.

Pharm Exec profiles Sanofi EVP Pascale Witz, tagged with the assignment to move a lumbering biopharma giant closer to the embrace of the patient perspective in healthcare.

Following Pharm Exec’s recent profile of the Express Scripts CMO, Dr. Steve Miller adds some further thoughts - on health reform, cost-effectiveness research, pharma’s reputation, and the obligations of government - to his incisive critique of industry pricing practises.

Merck KGaA CEO Stefan Oschmann spoke last week in New York as he accepted the two-year role as president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).